Approved indications: Xolair given subcutaneously is FDA-approved for moderate to severe persistent allergic asthma in patients 6 years and older whose symptoms remain uncontrolled on inhaled corticosteroids; chronic spontaneous (idiopathic) urticaria in patients 12 years and older not controlled with H1 antihistamines; chronic rhinosinusitis with nasal polyps in adults 18 years and older when intranasal corticosteroids are inadequate; and for reducing allergic reactions, including anaphylaxis, from accidental exposure in IgE-mediated food allergy in patients 1 year and older, alongside continued strict avoidance of trigger foods.

Off-label uses: Clinicians may also prescribe omalizumab off label for conditions such as severe allergic rhinitis, allergic bronchopulmonary aspergillosis, mast-cell disorders and recurrent anaphylaxis, atopic dermatitis, eosinophilic gastrointestinal disease and as an aid to allergen immunotherapy; evidence for these uses comes mainly from small trials and observational studies, so benefit is patient-specific and it remains unapproved for these indications.

Efficacy expectations: In allergic asthma and nasal polyps, patients typically begin to see fewer symptoms and exacerbations within about 4 to 12 weeks, often with reduced need for oral steroids or surgery compared with standard therapy alone; in chronic spontaneous urticaria, itch and hives may improve within 1 to 2 weeks but up to 3 months of treatment is usually allowed before judging response; in IgE-mediated food allergy, several months of regular injections can markedly increase the amount of allergen that can be tolerated without a reaction, lowering the risk from accidental exposures but not curing the allergy or allowing free eating of trigger foods. Overall, compared with other biologics targeting type 2 inflammation, Xolair has long real-world experience and is particularly effective when IgE-driven allergy is prominent across multiple organs.

General administration: Xolair is given as a subcutaneous injection into the thigh, abdomen (avoiding the area directly around the navel) or outer upper arm, with initial doses administered in a healthcare setting and, after at least three uneventful supervised injections, some patients or caregivers may be trained to use prefilled syringes or autoinjectors at home.

Typical dosing by indication: For moderate to severe allergic asthma in patients 6 years and older, chronic rhinosinusitis with nasal polyps in adults and IgE-mediated food allergy in patients 1 year and older, the usual dose range is 75 to 600 mg every 2 or 4 weeks based on body weight and baseline total IgE level; for chronic spontaneous urticaria in patients 12 years and older, the dose is 150 or 300 mg every 4 weeks and does not depend on IgE level or weight.

Special dosing instructions: In asthma and nasal polyps, inhaled and oral corticosteroids should not be stopped abruptly when Xolair is started and any dose reduction must be gradual under medical supervision; because treatment raises total IgE, IgE blood tests drawn after therapy begins cannot be used to recalculate dose, and doses greater than 150 mg are divided into multiple injections given at least 1 inch apart with rotation of injection sites.

Missed doses and overdose: If an injection is missed or delayed, patients should contact their prescriber as soon as possible to arrange the next dose rather than doubling up, as timing can usually be adjusted without restarting the regimen; suspected large overdoses are rare but should prompt urgent medical evaluation and, if available, consultation with a poison control center.

Common side effects: The most frequent problems are injection-site reactions (pain, redness, swelling or bruising), headache, joint or muscle pain, tiredness, dizziness, mild fever and upper respiratory or sinus infections; these are usually mild to moderate, start in the first days after an injection and often lessen over time.

Serious or rare adverse effects:

• Anaphylaxis (a severe allergic reaction) can occur at any time during treatment, most often within the first few doses; symptoms include trouble breathing, wheezing, chest tightness, feeling faint, rapid or weak heartbeat, swelling of the face, lips, tongue or throat and widespread hives, and require immediate emergency care.
• On rare occasions, patients develop serious systemic eosinophilia or vasculitis (sometimes resembling Churg–Strauss syndrome), or a serum-sickness–like reaction with fever, joint pain, rash and swollen lymph nodes days after an injection, which may require stopping the drug and medical treatment.
• Long-term safety studies suggest a possible small increase in serious cardiovascular and cerebrovascular events and an uncertain but probably low risk of malignancy, so clinicians weigh these potential risks carefully in people with significant baseline heart, brain or cancer risk.

Warnings and precautions: Xolair must not be used in anyone with a prior severe hypersensitivity reaction to omalizumab or its ingredients, and should be used cautiously in people with a history of anaphylaxis to other causes, parasitic (helminth) infections or significant cardiovascular disease; data in pregnancy and breastfeeding are limited, so use is generally reserved for situations where potential benefit outweighs risk, often with enrollment in a pregnancy registry. No specific dose adjustment is required for kidney or liver impairment, but experience is more limited in severe organ dysfunction, and some prefilled syringe needle caps contain latex, which is important for latex-allergic patients.

Relative safety: Overall, omalizumab is considered well tolerated for long-term use, with extensive worldwide experience and no strong signal for generalized immune suppression, organ toxicity or increased common infections compared with many traditional immunosuppressive drugs.

Side-effect reporting and safety updates: Patients should promptly tell their prescriber about any suspected side effects and may also report them directly to the FDA MedWatch program by phone or online; the Xolair Medication Guide and the FDA Drug Safety Communications website provide up-to-date information on known and emerging safety issues.

Drug and food interactions: Omalizumab is cleared by normal protein breakdown pathways and is not metabolized by cytochrome P450 enzymes or known to affect them, so it has no well-documented interactions with most prescription drugs, over-the-counter medicines, supplements or foods; alcohol has no specific interaction with Xolair but may worsen underlying asthma or liver disease and should be used cautiously.

Other therapies and procedures: Xolair is commonly used together with inhaled or intranasal corticosteroids, antihistamines, leukotriene modifiers and epinephrine autoinjectors, and it may be combined with allergen immunotherapy or oral food immunotherapy under specialist supervision to improve safety and effectiveness. Routine vaccinations, including COVID-19 vaccines, are generally allowed during treatment, though many experts prefer spacing vaccine and Xolair injections by at least a day so that any reaction can be clearly attributed.

Precautions and situations requiring extra care: Caution is advised in people with uncontrolled asthma, recent severe anaphylaxis, active or high-risk parasitic (helminth) infections, significant cardiovascular or cerebrovascular disease or a history of certain cancers; patients with known latex allergy should discuss use of prefilled syringes whose needle caps contain latex so that alternative devices or handling strategies can be used if needed.

Monitoring needs: Before starting Xolair, patients typically have total IgE level and body weight measured (for asthma, nasal polyps and food allergy dosing) and are screened for other medical conditions; during treatment, clinicians monitor control of asthma, hives, nasal and sinus symptoms, watch for signs of anaphylaxis, eosinophilia, vasculitis or cardiovascular events and usually observe patients in the clinic for a period after each injection, especially for the first several doses.

Q: How long does it take for Xolair to start working?
A: Many people notice some improvement within the first few weeks, but the full benefit for asthma, hives, nasal polyps or food allergy protection may take 2 to 3 months of regular injections.

Q: Will Xolair cure my asthma, hives or food allergies?
A: Xolair controls disease activity and reduces the risk and severity of reactions while you are receiving it, but it does not permanently cure asthma, chronic hives or food allergy, so symptoms often return gradually if treatment is stopped.

Q: Is Xolair a steroid or an immunosuppressant?
A: Xolair is not a steroid; it is a targeted monoclonal antibody against IgE and, unlike many traditional immunosuppressants, it does not broadly weaken the immune system or markedly increase everyday infection risk.

Q: Can I stop my other asthma or allergy medicines once I start Xolair?
A: You should continue your existing controller medicines, such as inhaled steroids or antihistamines, unless your clinician specifically tapers them, because stopping them too quickly can lead to worsening symptoms even after Xolair is begun.

Q: Can I give myself Xolair injections at home?
A: After at least three doses given safely in a clinic and if you or a caregiver can recognize and respond to anaphylaxis, your clinician may prescribe prefilled syringes or an autoinjector and train you to give injections at home.

Q: What should I do if I miss a Xolair injection?
A: Contact your clinic as soon as you realize the dose was missed; they will usually have you reschedule the injection promptly and then continue on your usual every-2- or every-4-week schedule without taking extra doses.

Storage: Keep unused Xolair prefilled syringes or autoinjectors in their original carton in a refrigerator at 36°F to 46°F (2°C to 8°C), protected from light; do not freeze, and do not use the product if it has been frozen, overheated (above about 77°F/25°C), discolored, cloudy or is past its expiration date.

Before injection: When ready to use, remove the carton from the refrigerator and let it warm to room temperature on its own for about 15 to 30 minutes, keeping it in the carton and out of direct sunlight; do not use external heat sources such as hot water or a microwave to warm it and do not shake the syringe.

Disposal: Use each syringe or autoinjector only once and immediately place it, with the needle attached, into a puncture-resistant sharps container; do not throw loose needles or syringes into household trash or recycling, and follow local or pharmacy take-back programs to dispose of full sharps containers while keeping all supplies out of reach of children and pets.